Dragonfly Tx Names Nicolai Wagtmann Chief Scientific Officer

Nicolai Wagtmann is joining Dragonfly Therapeutics to become the Cambridge, MA, biotech’s chief scientific officer. Wagtmann comes to Dragonfly from France-based Innate Pharma, where he was executive vice president and chief scientific officer. Before working at Innate, Wagtmann was vice president and head of cancer and immunobiology at Novo Nordisk. Earlier this month, Celgene (NASDAQ: [[ticker:CELG]]) reached a deal with Dragonfly to pay the tiny biotech $33 million up front for the right to co-develop up to four blood cancer drugs.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.